In the COMBAT-ALS trial for MN-166 in ALS, the final patient last visit for the double\u2011blind treatment period has been completed. Top-line data are planned for the end of 2026. No impact on the consolidated results for the year ending December 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4875","jir_company_name":"MediciNova, Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-24","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4875-20260924-01.pdf","jir_short_summary":"In the COMBAT-ALS trial for MN-166 in ALS, the final patient last visit for the double\u2011blind treatment period has been completed. Top-line data are planned for the end of 2026. No impact on the consolidated results for the year ending December 2026.","jir_summary":"### Key Points of the News\nAnnouncing that the final patient last visit for MN-166 in the COMBAT-ALS trial targeting ALS has been completed. The primary endpoints include CAFS scores, with top-line data expected to be released by the end of 2026. It is stated that there is no financial impact for the year ending December 2026.\n\n### Upcoming Developments and Outlook\nContinuing database lock and data analysis, advancing analyses of the double\u2011blind portion. Attention centers on the company\u2019s pipeline progress as it pursues potential expansion into neurological diseases such as ALS with new therapies.","jir_financial_highlights":"Impact on consolidated results for the year ending December 2026: Unknown (There is no impact on our consolidated results for the year ending December 2026)","jir_category":"","jir_hashtags":"#MediciNova, #ClinicalTrialProgress","jir_key_figures":"Top-line data publication planned: end of 2026\nDouble\u2011blind treatment period: 12 months\nOpen-label period: 6 months","jir_meta_title":"[MediciNova] Final Visit Completed for MN-166 ALS Therapeutic, COMBAT-ALS Trial | Topline End-2026","jir_meta_description":"MediciNova reports the final patient last visit for MN-166 in the COMBAT-ALS trial targeting ALS. Top-line data expected by the end of 2026. No impact on the consolidated results for the year ending December 2026.","jir_og_title":"ALS Therapy MN-166 Trial Progress; Year-End Topline Expected","jir_og_description":"Final patient last visit completed for MN-166 in the COMBAT-ALS trial. Topline expected by end-2026; no financial impact.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58821,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-122781","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n